Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 12,501–12,600 of 15,747
Molecular dynamics of the COVID-19 pandemic in Espirito Santo (Brazil) and border States
Torezani, R., Vargas, A. M. C., Ardisson, J. S., Pirovani, M. M., dos Santos, P. H. D., Paneto, G. G., & Bastos-Filho, T. (2022) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202264024 · Cited by 1
Impfstoffe gegen das SARS-Coronavirus-2
Welte, T. (2021) · Pneumo News · doi:10.1007/s15033-021-2716-x · Cited by 1
“Für mRNA-1273 und BNT162b2 wurden wesentliche PhaseIII-Daten, die dann für die Zulassung relevant waren, publiziert [6, 7, 8, 9].”
BackgroundMavridis, C., Aidonidis, G., & Kalogeridis, A. (2022) · Qeios · doi:10.32388/h4xgp2.8
Efficacy and Safety of COVID-19 Vaccines in Different Variants and Doses: A Systematic Review
Delam, H., Moghaddam, S., & Zare, R. (2022) · Epidemiology and Health System Journal · doi:10.34172/ehsj.2022.33 · Cited by 2
Zhang, Q., Tiwari, S. K., Wen, J. A., Wang, S., Wang, L., Li, W., Zhang, L., Rawling, S., Cheng, Y., Jokerst, J. V., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300524 · Cited by 1
Severe injection site reaction ensuing the first dose of mRNA COVID-19 vaccine
PIEROBON, E., SECHI, A., GERMI, L., PEZZOLO, E., TREVISAN, G., FELICIANI, C., & NALDI, L. (2022) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.22.07162-6 · Cited by 1
Lee, J., Kim, B., Woo, H., Kim, J. W., Jung, I., Park, S.-W., Kim, Y., Na, J., & Jung, S. T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00297 · Cited by 1
Zidan, M., Trinh, N. T., Desalegn, A. A., Smith, L. H., van Gelder, M. M. H. J., Nordeng, H., & Lupattelli, A. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127908 · Cited by 1
Lin, W.-K., Lin, S., Chang, Y.-H., Wang, F., Nguyen, P.-A., Phuc, P. T., Burton, W., Hien, N. T., Lin, C.-C., Lam, C., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12316-0 · Cited by 1
Ren, Z.-X., Nishimura, M., Tjan, L. H., Furukawa, K., Kurahashi, Y., Sutandhio, S., Aoki, K., Hasegawa, N., Arii, J., Uto, K., et al. (2022) · medRxiv · doi:10.1101/2022.01.13.22269203 · Cited by 1
Extending the interval of COVID-19 vaccine regimens in individuals aged 80 years or older
Iversen, P. L., & Bavari, S. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00205-1 · Cited by 1
Viral and host factors associated with SARS-CoV-2 disease severity in Georgia, USA
Carmola, L. R., Roebling, A. D., Khosravi, D., Langsjoen, R. M., Bombin, A., Bixler, B. J., Reid, A., Chen, C., Wang, E. B., Yang, L., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317972 · Cited by 1
Acer, Ö., Bahçe, Y. G., & Özüdoğru, O. (2024) · Current Microbiology · doi:10.1007/s00284-024-03689-7 · Cited by 2
“…was thought that a heterogeneous prime-boost vaccine combining the different platforms could offer comparable or possibly higher efficacy than the homologous CoronaVac (Sinovac Biotech) vaccine because the immunogenicity of the vaccines on the different platforms differs after vaccination [10, 11].”
Marković, O., Divac, A., Bukurecki, I., Branković, M., Jovanović, I., Đuran, P., & Zdravkovic, M. D. (2022) · Srpski medicinski casopis Lekarske komore · doi:10.5937/smclk3-35474 · Cited by 1
Izosimova, A. V., Shabalkina, A. V., Myshkin, M. Y., Shurganova, E. V., Myalik, D. S., Ryzhichenko, E. O., Фаритовна, С. А., Barsova, E. V., Shagina, I. A., Britanova, O. V., et al. (2024) · Vaccines · doi:10.3390/vaccines12040345 · Cited by 1
“In work by the group of Ugur Sahin, who was one of the leading developers of Pfizer’s SARS-CoV-2 vaccine [1], initially, this technology had been developed as a cure for B16 melanoma [2,3].”
BackgroundPostvaccination SARS-CoV-2 Infections among Healthcare Professionals: A Real World Evidence Study
Perrella, A., Mucherino, S., Guarino, I., Nerilli, M., Maraolo, A. E., Capoluongo, N., Coscioni, E., Trama, U., Menditto, E., & Orlando, V. (2022) · Vaccines · doi:10.3390/vaccines10040511 · Cited by 2
Devaux, C. A., Colson, P., Raoult, D., & Camoin‐Jau, L. (2023) · Preprints.org · doi:10.20944/preprints202311.1883.v1
Kumarasinghe, E. S., Hennessy, E. J., Danneman, M. W., Burke, K. E., Salerno, T., Giardino, E. E., Crawford, M. D., Thomas, E. L., Markaj, P. L., Mahmoudinobar, F., et al. (2026) · Small Science · doi:10.1002/smsc.70314 · Cited by 2
CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy
Billmeier, A., Khinvasara, K., Lang, F., Mohr, J., Reidenbach, D., Schork, M., Yildiz, I., & Diken, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2024416 · Cited by 1
Pohl, M. O., Busnadiego, I., Marrafino, F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.19.435806 · Cited by 1
Alorfi, N. M., & Ashour, A. (2022) · Clinical Pharmacology : Advances and Applications · doi:10.2147/cpaa.s356413 · Cited by 1
“However, a two-dose regimen of BNT162b2 will provide 95% protection against COVID19 in people aged 16 years or older.(17) No deaths were reported after first receipt of Pfizer-BioNTech COVID-19 vaccine.”
BackgroundAcute gastric and non-mesenteric colonic infarction following mRNA COVID-19 vaccination
Lee, T.-G., Kim, D. H., Yun, H. Y., & Ryu, D. H. (2022) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2022.04.142 · Cited by 1
Systems immune profiling of variant-specific vaccination against SARS-CoV-2Preprint
Peng, L., Park, J. J.-Y., Fang, Z., Zhou, X., Dong, M. B., Xiong, Q., Lin, C., & Chen, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.02.471028 · Cited by 1
Mechanistic model for improved performance of mRNA–LNPs formulated under turbulent mixing conditions
Mosesso, R., Randall, K., Vaidya, A., Tang, Y. J., Northen, T. R., Deliot, A., Sun, M., Goldman, R., Lyons, A., Liu, L., et al. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb00052e · Cited by 1
Cui, Z., Luo, Y. Q., Yi, Y., et al. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2528331 · Cited by 1
Koceniak, P., Chatys-Bogacka, Ż., Słowik, A., & Dziedzic, T. (2023) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2023.111426 · Cited by 2
Yang, Y., Chen, Y., Hong, M., Zou, R., Yao, J., Li, E., Wang, J., Ye, X., Xing, Y., Tang, Y., et al. (2026) · Emerging Microbes & Infections · doi:10.1080/22221751.2026.2631206 · Cited by 1
“Although early vaccines primarily targeted immunodominant regions of the spike (S) protein, particularly the receptor-binding domain (RBD) [1–5], the accumulation of mutations in these regions has facilitated immune evasion [6–9], thereby diminishing the efficacy of proto-type-strain-based vaccines…”
Gubae, K., Wondm, S. A., Birhane, W., Desalew, A. F., Moges, T. A., & Kiflu, M. (2022) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s388668 · Cited by 1
“Vaccination reduces hospitalizations and deaths after infection;(19,21,24) the manifestation of symptoms;(18,21) and the severity of illness.(19,23,25) Vaccination also reduces the risk of infectiousness.”
BackgroundResultSuzuki-Okutani, M., Okamura, S., Gis, T., Sasaki, H., Lee, S. P., Yoshida, A., Goto, S., Nakagawa, T., Ikawa, M., Kamitani, W., et al. (2024) · eLife · doi:10.7554/elife.97532.1 · Cited by 1
Nanoparticles in influenza research: a bibliometric analysis of global trends (2005 - 2025)
Zhang, Y., Lin, X., Wen, L., Zhang, J., Lin, J., Liu, X., Liu, Y., Xu, S., Lin, X., & Mo, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1715271 · Cited by 1
Mahmoud, Y., Hathout, A., Amen, R. A., Desouky, S., Shady, R. M., & Fahmy, H. M. (2023) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000386 · Cited by 1
COVID-19-ASSOCIATED CHANGES IN IMMUNITY AND LUNG LESIONS
Rekalova, О. M. (2023) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2023-31-2-13-23 · Cited by 4
Mavridis, C., Aidonidis, G., & Kalogeridis, A. (2022) · Qeios · doi:10.32388/h4xgp2.9
Nguyen, D. H., Tran, L. B., Viên, N. T., Hashan, M. R., Tripathi, A., Han, S. M., Nguyen, A. H., Trinh, N. B., Shabbo, E. E., Thang, D. X., et al. (2026) · Tropical Medicine and Health · doi:10.1186/s41182-025-00877-4 · Cited by 2
“The urgent need to develop COVID-19 vaccines and their unprejudiced distribution was the vital strategy for combating and controlling the crisis [3, 4].”
Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer
Samdaengpan, C., Sungkasubun, P., Chaiwiriyawong, W., Supavavej, A., Siripaibun, J., Phanthunane, C., Tantiyavarong, W., Lamlertthon, W., Ungtrakul, T., Tawinprai, K., et al. (2024) · JCO Global Oncology · doi:10.1200/go.23.00458 · Cited by 2
Chen, F., Zhang, Y., Zhang, Y., Li, Y., Ma, J., Qin, Y., Deng, S., Zhang, Y., Wang, D., Wang, H., et al. (2024) · Sexual Health · doi:10.1071/sh23191 · Cited by 1
YOSHINAGA, Y., Oe, M., Manabu, A. B. E., et al. (2023) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.e23010 · Cited by 1
Kamanzi, A., Bido, A. T., Zhang, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.683130 · Cited by 1
“Lipid nanoparticles (LNPs) are widely used to deliver mRNA-based therapies, 1 and their potential was highlighted by the rapid response to the COVID-19 pandemic with the Tozinameran (Comirnaty ® ) 2 and Elasomeran (Spikevax ® ) 3 vaccines.”
Paetzold, J., Krammer, F., von Laer, D., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-741944/v1 · Cited by 1
Efectividad de las vacunas contra la COVID-19 aplicadas a personal de salud
Barrera, M. D. M. A., Martínez-Serrano, V. N., & Pérez, F. H. (2022) · Revista CONAMED · doi:10.35366/108482 · Cited by 3
Wheeler, A., & Zakeri, S. A. (2022) · Journal of Hospital Librarianship · doi:10.1080/15323269.2022.2088948 · Cited by 1
“We now recognize that COVID-19 vaccines approved for use in the United Kingdom (including the Pfizer vaccine) are highly effective and safe in preventing serious COVID-19 complications such as requiring intubation and ventilation, or even death (6).”
BackgroundGenomics and precision medicine: Through a different prism
Moazam, F. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0006 · Cited by 1
Al-Busaidi, B., Riyami, I. A., Wazir, H. B., & Zakwani, I. S. A. (2024) · Sultan Qaboos University medical journal · doi:10.18295/squmj.1.2024.003 · Cited by 2
Fathi, A., & Mellinghoff, S. C. (2021) · Der Internist · doi:10.1007/s00108-021-01164-0 · Cited by 2
Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers
Hatabah, D., Gupta, S. L., Mantus, G. E., Sullivan, P. S., Heilman, S. S., Camacho-González, A., Leake, D., Le, U. Q., Griffiths, M., Norwood, C., et al. (2025) · Vaccines · doi:10.3390/vaccines13020163 · Cited by 1
Zanlourensi, C. B., & Boing, A. F. (2025) · Epidemiologia e Serviços de Saúde · doi:10.1590/s2237-96222025v34e20240329.en · Cited by 2
Madrid, J., Agarwal, P., Müller‐Peltzer, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3586395/v1 · Cited by 1
Schäfer‐Korting, M. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_696 · Cited by 3
Nagashima, S., Kitahara, Y., Sugiyama, A., et al. (2022) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.96.52 · Cited by 1
High seroconversion rate and SARS-CoV-2 Delta neutralization in PLWHIV vaccinated with BNT162b2
(2021) · doi:10.1101/2021.12.07.21267395 · Cited by 1
“seroconversion rate, percentage of patients who had a previous infection before vaccination, evolution of the antibodies [10] level after vaccination, comparison of the neutralizing capacity of antibodies between the different variants of SARS-CoV-2, correlation between the antibodies level and the neutralization tite…”
BackgroundStauber, D., Sosnick, L., Ma, Y.-T., Pimcharoen, S., Lawanprasert, A., Murthy, N., Myung, D., & Qi, L. S. (2025) · bioRxiv · doi:10.1101/2025.08.21.671629 · Cited by 1
RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airwaysPreprint
Gagné, M., Flynn, B., Honeycutt, C., Flebbe, D. R., Andrew, S., Provost, S. J., McCormick, L., Ry, A. V., McCarthy, E., Todd, J.-P. M., et al. (2023) · bioRxiv · doi:10.1101/2023.06.09.544432 · Cited by 2
Effect of transcript length, temperature, and lyophilization on mRNA-lipid nanoparticle stability
Chillara, M., Zhao, W., Dordick, J. S., & Przybycien, T. M. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104308 · Cited by 3
(2024) · doi:10.1101/2024.03.05.583494 · Cited by 1
“Specifically, the primary vaccination cycle with BNT162b2 or mRNA-1273 offered a 95% protection against the original SARS-CoV-2 strain in the general population [1,2].”
BackgroundQin, K., Honjo, K., Sherrill-Mix, S. A., Liu, W., Stoltz, R., Oman, A. K., Hall, L. A., Li, R., Sterrett, S., Frederick, E. R., et al. (2022) · medRxiv · doi:10.1101/2022.12.19.22283645 · Cited by 1
A better understanding on efficacy data of phase III trials for COVID-19 vaccines
Jin, P., Zhang, L., Li, J., & Zhu, F. (2021) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2021-0077 · Cited by 1
Wynberg, E., Han, A. X., Boyd, A. C., van Willigen, H. D. G., Verveen, A., Lebbink, R., van der Straten, K., Kootstra, N. A., van Gils, M. J., Russell, C. A., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4022243 · Cited by 1
COVID-19 Contact Tracing as an Indicator for Evaluating a Pandemic Situation: Simulation Study
Marques‐Cruz, M., Nogueira-Leite, D., Alves, J. M., Fernandes, F., Fernandes, J. M., Almeida, M. Â., Correia, P. C., Perestrelo, P., Cruz-Correia, R. J., & Barros, P. P. (2023) · JMIR Public Health and Surveillance · doi:10.2196/43836 · Cited by 2
Immunological heterogeneity informs estimation of the durability of COVID-19 vaccine protectionPreprint
de Cellès, M. D., Wong, A., Guevara, L. B., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-566774/v1 · Cited by 1
“[0,10) [10,20) [20,30) [30,40) [40,50) [50,60) [60,70) 70+ Age group (years) V a lu e ● ● Susceptibility to infection Clinical fraction (severity)”
BackgroundMethodInfluentialKeskin, B. B., Liu, S., Du, P.-X., Tsai, P.-S., Ho, T., Su, W., Lin, P.-C., Shih, H.-C., Weng, K.-P., Yang, K. D., et al. (2023) · The Analyst · doi:10.1039/d3an00802a · Cited by 1
Cross, R. M., Wiethoff, C. M., Brown‐Augsburger, P., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2285240/v1 · Cited by 1
Comparison of Clinical Progress of Covid-19 Patients Followed in the Hospital by Vaccination Status
YİĞİT, S. E., GÖKMEN, İ. B., Okuturlar, Y., et al. (2022) · Turkish Journal of Internal Medicine · doi:10.46310/tjim.1073683 · Cited by 1
Wang, W., Rui, J., Song, J., Zhang, X., Zhou, S.-N., Wang, F., & Fu, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1056884 · Cited by 1
“A multinational, observer-blinded trial found similar vaccine efficacy across different subgroups defined by age (Polack et al., 2020).”
BackgroundImmunogenicity after heterologous third dose COVID‐19 vaccination in a heart transplant recipient
Mehta, S. A., Reyentovich, A., Montgomery, R. A., Segev, D. L., Gebel, H. M., Bray, R. A., Samanovic, M. I., Cornelius, A. R., Mulligan, M. J., & Herati, R. S. (2022) · Clinical Transplantation · doi:10.1111/ctr.14605 · Cited by 1
Albogami, Y., Alalwan, A., Batais, M. A., Alabdulkareem, K. I., & Alalwan, A. A. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.09.014 · Cited by 1
Ma, J., Li, M., Xie, Z., & Li, D. (2025) · Decoding Infection and Transmission · doi:10.1016/j.dcit.2025.100048 · Cited by 2
Prophylactic Treatment of COVID-19 in Care Homes Trial (PROTECT-CH)Preprint
Bath, P. M., Ball, J. K., Boyd, M., Gage, H., Glover, M. J., Godfrey, M., Guthrie, B., Hewitt, J., Howard, R. J., Jaki, T., et al. (2022) · medRxiv · doi:10.1101/2022.08.29.22279359 · Cited by 1
“Nevertheless, outbreaks of infection have continued, and prophylaxis measures were introduced, especially pre-exposure prophylaxis with vaccination.(5,6) By December 2021, more than 126 million doses of vaccine had been delivered in the UK, this including first, second, third and booster injections.”
BackgroundContreras, A., McIver, W. J., Brown, T. P., Ji, C., Booth, S. J., Fothergill, R. T., Perkins, G. D., & Couper, K. (2025) · Resuscitation · doi:10.1016/j.resuscitation.2025.110823 · Cited by 2
Developing Mucosal Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2: What Will It Take?
Edwards, K. M., & Neuzil, K. M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac935 · Cited by 1
Yıldız, Y., Yaşar, E., Öztürk, E., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.70030 · Cited by 1
Masuta, Y., Minaga, K., Otsuka, Y., Okai, N., Hara, A., Masaki, S., Nagai, T., Honjo, H., Kudo, M., & Watanabe, T. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.23-26 · Cited by 1
“(2,3) However, immunization with these mRNA vaccines is accompanied by various adverse events.”
BackgroundYazdani, A., Mirmosayyeb, O., Sadeghi, M., et al. (2024) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2024.19.2.410 · Cited by 1
CGM23 corresponds to a pan-coronavirus lipopeptide inhibitor potently inhibiting virion fusion
Matsui, Y., Schwarzer, R., Montaño, M., Helmy, E. W., Suryawanshi, R. K., Taha, T. Y., Wang, Y., Angel, Y., Adler, M., Sassano, M. F., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115334 · Cited by 2
“10,11 In particular, the Omicron family of variants has proven remarkably prone to evading vaccine-acquired immunity and causing breakthrough infections.”
Axillary Adenopathy Secondary to SARS-CoV-2 Vaccination: a Case Report
Koff, A., & Inaty, H. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01143-y · Cited by 2
A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma
Stauber, D., Sosnick, L., Ma, Y., Pimcharoen, S., Lawanprasert, A., Murthy, N., Myung, D. J., & Qi, L. S. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201151 · Cited by 6
“55,56 Liver tropism of many clinically validated LNPs might also be advantageous for UM, whose metastases localize to the liver in >90% of patients, yet direct ocular (2) immune activation profiles after single and repeat dosing, particularly activation of innate RNA-sensing pathways that could…”
Khaja, A. S. S., Zafar, M., Almansour, M., Alsohail, H., Almansour, I., & Saleem, M. (2022) · Medical Science · doi:10.54905/disssi/v26i127/ms382e2459 · Cited by 1
Caetano, B. L. L., Pinto, P. B. A., Pacheco, A. R., Lage, A. R., Pereira, A., Nascimento, A. V. P., Machado, T. R., Paulino, A., Medeiros, T. L., Fernandes-Siqueira, L. O., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603612 · Cited by 2
Edwards, E. S. J., Gugasyan, R., Varese, N. P., Sun, S., Canning, J. E., Blight, E. G., Aui, P. M., Boo, I., Turville, S. G., Aggarwal, A., et al. (2025) · medRxiv · doi:10.1101/2025.11.09.25339598 · Cited by 1
An Executed Plan to Combat COVID-19 in the United States
Hartman, W. R. (2022) · Advances in Anesthesia · doi:10.1016/j.aan.2022.07.002 · Cited by 1
Ji, J.-H., Shin, S.-H., Park, Y., Park, J.-H., Park, J. J., Cheon, J. H., Kim, T., Kang, S.-B., Park, S. H., & Park, S. (2024) · Intestinal Research · doi:10.5217/ir.2023.00077 · Cited by 1
Fukunaga, Y., Saito-Sasaki, N., Ohta, E., & Sawada, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1721035 · Cited by 1
What Is the Role of COVID-19 Monoclonal Antibody Programs in Promoting Posttreatment Vaccination?
Cowman, K., Golia, A., Guo, Y., Simpson, R., Braithwaite, C., Sunu, E., Ros, T., Rodriguez, M. A., Brown, N., Laboy, E., et al. (2023) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000001216 · Cited by 1
Optimization of Synthesis of Modified mRNA
Yoo, J., & Zangi, L. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2707-5_7 · Cited by 2
Pandemic Viruses at Hajj: Influenza and COVID-19
Alfelali, M., Koul, P. A., & Rashid, H. (2021) · Springer eBooks · doi:10.1007/978-3-319-74365-3_50-1 · Cited by 1
Janes, H., Gao, F., & Luedtke, A. R. (2021) · Biometrics · doi:10.1111/biom.13542
“Indeed, the available data do not appear to suggest meaningful HVE for the COVID-19 vaccines currently under emergency use authorization in the United States (Polack et al., 2020; Baden et al., 2021; Sadoff et al., 2021), with the exception of potential variation in efficacy by viral variants—an issue we will discuss…”
BackgroundVaccine protection and how we measure it
Ni, B., Yanis, A., Chappell, J. D., & Halasa, N. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13748 · Cited by 1
Vaccines After an Emergency Use Authorization (EUA): Modern Evidence Generation Approaches
Zariffa, N. M.-D., & Russek‐Cohen, E. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00290-z · Cited by 1
Bukharin, G. A., Буданова, У. А., Гезимахмаевна, Д. З., Dubrovin, E. V., & Sebyakin, Y. L. (2024) · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology · doi:10.1134/s1990747824700314 · Cited by 1
“The successful clinical application of mRNA vaccines based on liposomal carriers from Pfizer-BioNTech and Moderna against COVID-19 corona-virus infection demonstrated their great potential for the development of such drugs [8, 9].”
mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network
Muller, M. P., Soe, P., Shulha, H. P., Isenor, J. E., Valiquette, L., Sadarangani, M., Vanderkooi, O. G., Kellner, J. D., Top, K. A., Serres, G. D., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128630 · Cited by 2
Moriyama, Y., Ishikane, M., Ueno, M., Matsunaga, A., Ishizaka, Y., Arashiro, T., Kanno, T., Suzuki, T., & Kimura, K. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.02.003 · Cited by 1
“Although the BNT162b2 vaccine is highly effective at preventing SARS-CoV-2 infection, disease, and severe disease [6], it is thought to be less effective at preventing infection with the delta variant than at preventing infection with the wild-type and alpha variant of SARS-CoV-2 [10,11].”
BackgroundHanafy, A. S., Embaby, A., Salem, S. M., Behiry, A., Ebrahim, H. A., Elkattawy, H. A., Abed, S. Y., Almadani, M. E., & El‐Sherbiny, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247578 · Cited by 1
Hsiao, S.-H., Sue, Y., Kao, C., Chang, H., Lin, Y., Hung, C.-S., Hsieh, Y., Hong, S., Chung, C., Chang, J., et al. (2023) · Vaccines · doi:10.3390/vaccines11071161 · Cited by 1
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.